CEO of Workday Inc (NASDAQ:WDAY) Aneel Bhusri sold 75,000 shares of WDAY on 03/02/2018 at an average price of $127.23 a share. The total sale was $9.5 million.
Workday Inc is a SaaS provider offering enterprise resource planning, or ERP, software for medium and large enterprises. The company’s product portfolio is built around human capital and financial management software. Workday Inc has a market cap of $28.55 billion; its shares were traded at around $135.95 with and P/S ratio of 13.16.
CEO Recent Trades:
CEO Aneel Bhusri sold 75,000 shares of WDAY stock on 03/02/2018 at the average price of $127.23. The price of the stock has increased by 6.85% since.
CFO Recent Trades:
Co-President & CFO Robynne Sisco sold 38,750 shares of WDAY stock on 03/01/2018 at the average price of $126.1. The price of the stock has increased by 7.81% since.
Directors and Officers Recent Trades:
Co-President Gomez Luciano Fernandez sold 1,709 shares of WDAY stock on 02/15/2018 at the average price of $124.23. The price of the stock has increased by 9.43% since.
For the complete insider trading history of WDAY, click here
Best Heal Care Stocks To Watch For 2019: Vitality Biopharma (VBIO)
- [By Phil Saunders]
Vitality Biopharma, Inc. (OTCBB: VBIO) recent ascent as a strong small cap player in Cannabis pharma, is part of a boom in Cannabis-based pharmaceuticals making announcements about unique and innovative delivery systems being tested for such ailments as Epilepsy, Multiple Sclerosis, and Crohns disease. But it is important to understand how the industry is evolving in the United States and Canada and what that might mean when realizing valuation and the evolution of government policies which still vary from jurisdiction to jurisdiction, making access to Cannabis and the pricing model still a big question moving forward.
- [By James E. Brumley]
In mid-September, Vitality Biopharma Inc (OTCMKTS:VBIO) announced it was going to take aim at the development of an alternative to opioids as a means of treating pain. At the time, there was little doubt that the company’s cannabinoid science was capable of doing so. What wasn’t clear to VBIO shareholders was exactly how that might happen…. meaning what sort of drug might Vitality Biopharma come up with.
We got the first of what will likely be several answers to the question today. Per today’s press release, Vitality Biopharma intends to come up with a treatment for narcotic bowel syndrome, which is a severe form of (ironically enough) opiate-induced abdominal pain.
As a refresher, Vitality Biopharma was the name we introduced to you back on August 8th, pointing out it had developed a whole new way of making cannabinoid-based medicines. Their versions offer all the upsides of cannabinoids, but without the psychotropic (“getting high’) effects, and without some of the common downsides associated with these pharmaceuticals… like mouth and skin lesions.
There are even bigger advantages to Vitality Biopharma’s science, however. Namely, since these drugs are prodrugs and aren’t activated until in the body, they allow for targeted delivery to the GI tract (yet can also selectively target other body parts, even as far away from the GI tract as the brain). Perhaps more than anything though, these drugs are orally-administered by virtue of being highly soluble, making them easy to use.
It’s this nuance that makes Vitality Biopharma’s recently-announced intention so interesting, and compelling.
Studies have found that up to 81% of patients treated with opiates have functional bowel disorders, with more than half — 58% to be exact — of opiate users reporting chronic abdominal pain stemming from the use of their prescribed painkillers. Considering 200 million opioid prescriptions are filled every year in the United States alo
- [By Matthew Briar]
Back in September, Vitality Biopharma Inc (OTCMKTS:VBIO) CEO Robert Brooke officially announced his company would be entering the painkiller market, specifically taking aim at the development of an alternative to opioids. His specific words? “Opiates are one of the key classes of drugs we’re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions…”
- [By Jim Robertson]
That’s why its worth pointing out that just yesterday, small cap cannabinoid prodrug pharmaceutical stock Vitality Biopharma, Inc. (OTCQB: VBIO) announced the appointment of Tracy Rockney, J.D. to the position of Senior Regulatory Advisor. In addition to being the Co-Founder & Chief Operating Officer of OneSource Regulatory, a regulatory consulting firm, Rockney was previously:
Best Heal Care Stocks To Watch For 2019: Luby's, Inc.(LUB)
- [By Monica Gerson]
Luby’s, Inc. (NYSE: LUB) is expected to post earnings for the latest quarter.
Simulations Plus, Inc. (NASDAQ: SLP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $5.00 million.
Best Heal Care Stocks To Watch For 2019: Senior Housing Properties Trust(SNH)
- [By Matthew Frankel]
Healthcare real estate is just as defensive of an investment as net-lease retail, and has even more growth potential in the years ahead. One beaten-down healthcare REIT that I have my eye on in 2017 is Senior Housing Properties Trust (NASDAQ:SNH).
Best Heal Care Stocks To Watch For 2019: Microsoft Corporation(MSFT)
- [By Paul Ausick]
Microsoft Corp. (NASDAQ: MSFT) traded up 2.24% at $91.39. The stock’s 52-week range is $64.85 to $97.24. Volume was about equal to the daily average of around 33 million. CEO Satya Nadella has reorganized the software giant around its cloud software business.
- [By Virendra Singh Chauhan]
Sunnyvale, California-based AMD (NSDQ:AMD) recently unveiled their machine learning strategy with the launch of the new Radeon Instinctaccelerators, MIOpen library and the ROCm software (launched earlier). Artificial intelligence (AI), Machine Learning(ML) and Deep Learning(DL) have become the new buzzwords in the tech space. Most major technology companies including Alphabet (NSDQ:GOOGL), Microsoft (NSDQ:MSFT), International Business Machines (NYSE:IBM), Facebook (NSDQ:FB) have taken the AI plunge, so it’s no surprise that AMD unveiled their machine learning strategy. It was only a matter of time. So how exactly does this alter AMD’s prospects? And what does it mean for AMD stock investors?
- [By Paul Ausick]
Microsoft Corp. (NASDAQ: MSFT) traded down 2.72% at $94.15. The stock’s 52-week range is $64.12 to $97.24, and the high was posted early this morning. Volume was equal to the daily average of nearly 30 million shares. Court documents released today show that women at Microsoft’s U.S. operations filed 238 gender discrimination or sexual harassment actions against the company between 2010 and 2016.